This old version of Proteopedia is provided for student assignments while the new version is undergoing repairs. Content and edits done in this old version of Proteopedia after March 1, 2026 will eventually be lost when it is retired in about June of 2026.
Apply for new accounts at the new Proteopedia. Your logins will work in both the old and new versions.
4ot9
From Proteopedia
crystal structure of the C-terminal domain of p100/NF-kB2
Structural highlights
Disease[NFKB2_HUMAN] Note=A chromosomal aberration involving NFKB2 is found in a case of B-cell non Hodgkin lymphoma (B-NHL). Translocation t(10;14)(q24;q32) with IGHA1. The resulting oncogene is also called Lyt-10C alpha variant. Note=A chromosomal aberration involving NFKB2 is found in a cutaneous T-cell leukemia (C-TCL) cell line. This rearrangement produces the p80HT gene which encodes for a truncated 80 kDa protein (p80HT). Note=In B-cell leukemia (B-CLL) cell line, LB40 and EB308, can be found after heterogeneous chromosomal aberrations, such as internal deletions. Function[NFKB2_HUMAN] NF-kappa-B is a pleiotropic transcription factor present in almost all cell types and is the endpoint of a series of signal transduction events that are initiated by a vast array of stimuli related to many biological processes such as inflammation, immunity, differentiation, cell growth, tumorigenesis and apoptosis. NF-kappa-B is a homo- or heterodimeric complex formed by the Rel-like domain-containing proteins RELA/p65, RELB, NFKB1/p105, NFKB1/p50, REL and NFKB2/p52. The dimers bind at kappa-B sites in the DNA of their target genes and the individual dimers have distinct preferences for different kappa-B sites that they can bind with distinguishable affinity and specificity. Different dimer combinations act as transcriptional activators or repressors, respectively. NF-kappa-B is controlled by various mechanisms of post-translational modification and subcellular compartmentalization as well as by interactions with other cofactors or corepressors. NF-kappa-B complexes are held in the cytoplasm in an inactive state complexed with members of the NF-kappa-B inhibitor (I-kappa-B) family. In a conventional activation pathway, I-kappa-B is phosphorylated by I-kappa-B kinases (IKKs) in response to different activators, subsequently degraded thus liberating the active NF-kappa-B complex which translocates to the nucleus. In a non-canonical activation pathway, the MAP3K14-activated CHUK/IKKA homodimer phosphorylates NFKB2/p100 associated with RelB, inducing its proteolytic processing to NFKB2/p52 and the formation of NF-kappa-B RelB-p52 complexes. The NF-kappa-B heterodimeric RelB-p52 complex is a transcriptional activator. The NF-kappa-B p52-p52 homodimer is a transcriptional repressor. NFKB2 appears to have dual functions such as cytoplasmic retention of attached NF-kappa-B proteins by p100 and generation of p52 by a cotranslational processing. The proteasome-mediated process ensures the production of both p52 and p100 and preserves their independent function. p52 binds to the kappa-B consensus sequence 5'-GGRNNYYCC-3', located in the enhancer region of genes involved in immune response and acute phase reactions. p52 and p100 are respectively the minor and major form; the processing of p100 being relatively poor. Isoform p49 is a subunit of the NF-kappa-B protein complex, which stimulates the HIV enhancer in synergy with p65.[1] Publication Abstract from PubMedDegradation of I kappaB (kappaB) inhibitors is critical to activation of dimeric transcription factors of the NF-kappaB family. There are two types of IkappaB inhibitors: the prototypical IkappaBs (IkappaBalpha, IkappaBbeta, and IkappaBepsilon), which form low-molecular-weight (MW) IkappaB:NF-kappaB complexes that are highly stable, and the precursor IkappaBs (p105/IkappaBgamma and p100/IkappaBdelta), which form high-MW assemblies, thereby suppressing the activity of nearly half the cellular NF-kappaB [Savinova OV, Hoffmann A, Ghosh G (2009) Mol Cell 34(5):591-602]. The identity of these larger assemblies and their distinct roles in NF-kappaB inhibition are unknown. Using the X-ray crystal structure of the C-terminal domain of p100/IkappaBdelta and functional analysis of structure-guided mutants, we show that p100/IkappaBdelta forms high-MW (IkappaBdelta)4:(NF-kappaB)4 complexes, referred to as kappaBsomes. These IkappaBdelta-centric "kappaBsomes" are distinct from the 2:2 complexes formed by IkappaBgamma. The stability of the IkappaBdelta tetramer is enhanced upon association with NF-kappaB, and hence the high-MW assembly is essential for NF-kappaB inhibition. Furthermore, weakening of the IkappaBdelta tetramer impairs both its association with NF-kappaB subunits and stimulus-dependent processing into p52. The unique ability of p100/IkappaBdelta to stably interact with all NF-kappaB subunits by forming kappaBsomes demonstrates its importance in sequestering NF-kappaB subunits and releasing them as dictated by specific stimuli for developmental programs. p100/IkappaBdelta sequesters and inhibits NF-kappaB through kappaBsome formation.,Tao Z, Fusco A, Huang DB, Gupta K, Young Kim D, Ware CF, Van Duyne GD, Ghosh G Proc Natl Acad Sci U S A. 2014 Nov 11;111(45):15946-51. doi:, 10.1073/pnas.1408552111. Epub 2014 Oct 27. PMID:25349408[2] From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine. References
| ||||||||||||||||||
